PPM1D and AL amyloidosis: However, unlike reports in patients heavily exposed to cytotoxic agents, we did not see a predominance of TP53 and PPM1D mutations expand, likely reflecting the unique plasma cell–directed mechanism of action of most agents employed in the treatment of multiple myeloma (18, 44).